Press release Oncology Venture to present a poster at upcoming PARP & DDR Inhibitor Summit on clinical development of 2X-121

NEXT STORY
CORRECTION: Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
PREV STORY
Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Shire plc: Director/PDMR Shareholding

Director/PDMR Shareholding July 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of ...

author_avatar
NASDAQ Market News

Clearside Biomedical, Inc. to Present Data from Phase 2 (DOGWOOD) Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis at the 2016 ASRS Annual Meeting

ALPHARETTA, Ga., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage ...

author_avatar
NASDAQ Market News

Dynavax to Present at the 2018 Cantor Global Healthcare Conference

BERKELEY, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced ...

author_avatar
NASDAQ Market News